Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,715.60
(
0.96%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
110.59
(
0.21%
)
Bitcoin
77,122.61
(
1.04%
)
News Focus
News Focus
Post# of 823814
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

dstock07734

Send PM Follow Ignore
Followers 76
Posts 6475
Boards Moderated 0
Alias Born 05/25/2021

dstock07734

Re: HyGro post# 566859

Saturday, 02/11/2023 10:08:31 AM

Saturday, February 11, 2023 10:08:31 AM

Post# of 823814
"Eight of the 232 patients (3.4%) receiving DCVax-L were treated with tumor-treating fields (TTF) following recurrence. Four of those 8 patients (50.0%) continued receiving DCVax-L while using the TTF device after recurrence and survived from 22.6 to more than 72.7 months from randomization. Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization."

What does this tell you?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News